Výsledky vyhledávání - "O Iborra Egea"

P181 CARDIAC PROTECTION BY PIRFENIDONE AFTER MYOCARDIAL INFARCTION: A BIOINFORMATIC ANALYSIS

Autor: A Aimo, O Iborra–Egea, N Martini, C Galvez–monton, S Burchielli, G Panichella, C Passino, M Emdin, A Bayes–Genis

Publikováno v: European Heart Journal Supplements. 24

Purpose Left ventricular (LV) remodeling after myocardial infarction (MI) is promoted by an intense fibrotic response, which could be targeted by an anti–fibrotic drug such as pirfenidone. Methods We explored the relationship between protein modula

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7cf6725f75185940447692a5814637ae
https://doi.org/10.1093/eurheartj/suac012.173

Zobrazit plný text záznamu

Empagliflozin in heart failure with preserved ejection fraction: decoding its molecular mechanism of action using artificial intelligence

Autor: A Bayes Genis, D.A Pascual Figal, O Iborra Egea, A Cserkoova, Mar Domingo, Julio Núñez, Germán Cediel, E Santiago Vacas, Pau Codina, J Lupon, E Revuelta Lopez, G Spitaleri

Publikováno v: European Heart Journal. 42

Rationale The use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) to treat heart failure with preserved ejection fraction (HFpEF) is under investigation in ongoing clinical trials, but the exact mechanism of action is unclear. Here we aimed to

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b2b14c88c91ef7d39829c3a9775c2c2b
https://doi.org/10.1093/eurheartj/ehab724.0727

Zobrazit plný text záznamu

Mechanisms of cardiac protection by pirfenidone in the post-myocardial infarction setting

Autor: C Galvez-Monton, Alberto Aimo, O Iborra Egea, Michele Emdin, Antoni Bayes-Genis, Silvia Burchielli, Claudio Passino

Publikováno v: European Heart Journal
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname

Background A high proportion of patients with ST-segment elevation myocardial infarction (STEMI) experience adverse left ventricular (LV) remodelling despite guideline-recommended therapy. An excessive and dysregulated fibrotic response is involved i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d4110945d1a1d2d3191c22c3eb08402
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=3633

Zobrazit plný text záznamu

Rationale for CDR132L, an antisense inhibitor of miR-132, for a novel therapy for ventricular remodelling after myocardial infarction

Autor: A Aimo, O Iborra Egea, A Bayes-Genis, C Passino, M Emdin

Publikováno v: European Heart Journal
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname

Background Heart failure (HF) development is a common complication of myocardial infarction (MI), which warrants a search for novel therapies able to prevent left ventricular remodelling after an MI. CDR132L is a synthetic antisense inhibitor of miR-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e8f87d8f05678fc591a748902b7e0854
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=3574

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání